Stay updated with breaking news from Interim Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biophytis / Key word(s): Annual ResultsBiophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives 07-Apr-2022 / 08:00 CET/CESTBiophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives Success of Nasdaq IPO in February 2021 €23.9M o...
DGAP-News: ABIVAX / Key word(s): Study results Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintena...
Interim Analysis in Phase 2 CANAL Trial Showed Primary Efficacy Endpoint of Cough Reduction in Idiopathic Pulmonary Fibrosis was Highly Statistica...
Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022 First Interim Analysis of 418 Evaluable Patients Remains on Track for the First Half of 2022 Data
Investegate announcements from NuCana plc, NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study